Prognostic Significance of MicroRNA-375 Downregulation in Solid Tumors: A Meta-Analysis

Abstract

Objective. Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may play an important role as prognostic biomarker of cancers. We performed a meta-analysis to evaluate the impact of miR-375 expression in solid tumors on patients' overall survival (OS). Methods. Studies were identified by searching PubMed, Embace, and Cochrane Library (last search update was in May 2014) and were assessed by further quality evaluation. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS. Results. Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48–2.45, P < 0.001). Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69–2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31–2.24, P < 0.001). Conclusions. The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker.

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

“…44,48,51,54,[56][57][58][59] In NSCLC, miRNA-375 is associated with poor prognosis. 43,44,60 Interestingly, miRNA-375 is strongly associated with the Wnt/ b-catenine pathway 49 and the Hippo pathway, 59,[61][62][63] known to be involved in ICIs resistance. [64][65][66][67][68][69][70] Moreover, miRNA-375 targets the JAK2 gene, 62,71 involved in the IFN-g and TNF-a pathways, key-regulators of cytotoxic CD8C immune response.…”

Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer

“…To this day, it is unclear whether an under-expression of miR-375 offers a poor prognosis [39, 44], or whether its role for prognosis is insignificant or if its expression is not related to cancer outcome [45][46][47][48]. miR-375 usage as a potential biomarker in cancer is still unclear and should furthermore be investigated via meta-analyses or prospective multicenter studies with a larger sample size, even if low-expressions have been correlated with poor survival [49]. To exemplify its role in oncogenesis, a restored function of miR-375 in hepatocellular carcinoma inhibited tumor proliferation, invasion potential and migration, and facilitated apoptosis [36].…”

Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs)

“…Liquid biopsy is critical for the evaluation of cancer progression [1][2][3]. Circulating tumor cells (CTCs) are a major player in metastatic procedure and they are responsible for the hematopoietic dissemination of tumor cells [2][3][4][5][6][7].…”